Revelation Biosciences(US:REVB)2025-11-06 21:28Financial Position - As of September 30, 2025, Revelation had $12.7 million in cash and cash equivalents, up from $6.5 million as of December 31, 2024, primarily due to net cash proceeds from a public offering and warrant inducement[2]. - The total assets of Revelation as of September 30, 2025, were $12.86 million, compared to $6.62 million as of December 31, 2024[12]. - Revelation's accumulated deficit as of September 30, 2025, was $(46.91) million, up from $(40.51) million as of December 31, 2024[12]. Operating Performance - Net cash used for operating activities for the nine months ended September 30, 2025, was $6.3 million, a significant decrease from $14.6 million for the same period in 2024[2]. - Revelation's net loss for the three months ended September 30, 2025, was $1.9 million, or $(1.77) per share, compared to a net loss of $2.2 million, or $(40.15) per share for the same period in 2024[2][10]. - For the nine months ended September 30, 2025, the net loss was $6.4 million, or $(9.76) per share, compared to a net loss of $13.3 million, or $(354.05) per share for the same period in 2024[2][10]. - Total operating expenses for the three months ended September 30, 2025, were $1.94 million, compared to $1.80 million for the same period in 2024[10]. Development Focus - The company is focused on the development of Gemini, which aims to treat acute kidney injury, chronic kidney disease, and other inflammatory conditions[4][7]. - Revelation plans to meet with the FDA later this year to discuss the clinical development path for Gemini[2]. Fundraising Activities - Revelation received gross proceeds of $9.6 million from warrant inducement in September 2025[5].